Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$29.51 - $46.26 $519,376 - $814,176
-17,600 Reduced 20.09%
70,000 $3.24 Million
Q2 2024

Aug 14, 2024

BUY
$22.21 - $34.48 $1.61 Million - $2.5 Million
72,600 Added 484.0%
87,600 $2.85 Million
Q4 2023

Feb 14, 2024

SELL
$24.82 - $32.88 $372,300 - $493,200
-15,000 Reduced 50.0%
15,000 $487,000
Q3 2023

Nov 14, 2023

BUY
$21.97 - $33.8 $659,100 - $1.01 Million
30,000 New
30,000 $817,000
Q2 2022

Aug 15, 2022

SELL
$17.33 - $25.3 $1.21 Million - $1.77 Million
-70,000 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$16.53 - $25.21 $578,550 - $882,350
35,000 Added 100.0%
70,000 $1.58 Million
Q4 2021

Feb 11, 2022

BUY
$17.1 - $23.34 $598,500 - $816,900
35,000 New
35,000 $693,000
Q2 2021

Aug 16, 2021

SELL
$19.97 - $24.43 $1.3 Million - $1.59 Million
-65,000 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$23.49 - $30.56 $1.53 Million - $1.99 Million
65,000 New
65,000 $1.55 Million
Q4 2020

Feb 16, 2021

SELL
$16.78 - $27.3 $419,500 - $682,500
-25,000 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$12.46 - $19.98 $124,600 - $199,800
-10,000 Reduced 28.57%
25,000 $435,000
Q2 2020

Aug 14, 2020

SELL
$11.0 - $18.26 $192,500 - $319,550
-17,500 Reduced 33.33%
35,000 $590,000
Q1 2020

May 15, 2020

SELL
$10.11 - $14.04 $141,540 - $196,560
-14,000 Reduced 21.05%
52,500 $625,000
Q4 2019

Feb 13, 2020

BUY
$12.06 - $16.96 $801,990 - $1.13 Million
66,500 New
66,500 $805,000
Q3 2019

Nov 14, 2019

SELL
$10.41 - $14.66 $416,400 - $586,400
-40,000 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$9.78 - $12.76 $195,600 - $255,200
20,000 Added 100.0%
40,000 $446,000
Q1 2019

May 14, 2019

BUY
$10.03 - $15.71 $200,600 - $314,200
20,000 New
20,000 $235,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $6.27B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.